Professor, Internal Medicine, University of Michigan Medical School
Oncology
Dr. Moshe Talpaz, MD
|
|
Give Review
Dr. Moshe Talpaz practices Oncology. He went to The Hebrew University of Jerusalem Hadassah Medical School. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Moshe Talpaz is also published. He has 23 publications published. The lastest publication: "Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia InVivo.' He is registered with Medicare.
Publications
- The interferon-alpha revival in CML.
- Targeting deubiquitinase activity with a novel small molecule inhibitor as therapy for B-Cell malignancies.
- Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo.
- Three-year efficacy, oVerall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study.
- Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.
- Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple Myeloma (MM-I).
- Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.
- Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid Leukemia.
- First-line and second-line management of chronic myelogenous Leukemia.
- Hematology clinic: chronic myelogenous Leukemia.
- Activating ESR1 mutations in hormone-resistant metastatic breast Cancer.
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias.
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
- Ponatinib in patients with refractory Acute myeloid leukaemia: findings from a phase 1 study.
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial.
- Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological Malignancies.
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers.
- Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced Myeloid malig...
- Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.
- Re-emergence of interferon-α in the treatment of chronic myeloid Leukemia.
- Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid Leukemia in blast phase.
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Group Employees PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Emblem Health
- First Health (Coventry Health Care) PPO
- Frontpath Health Coalition
- Health Alliance
- Preferred PPO
- HealthPartners
- Choice Care PPO
- Medicaid
- Medical Mutual of Ohio
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- NGS CoreSource
- Paramount
- PHP-Physicians Health Plan
- Principal Life
- Priority PPO
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
The Hebrew University of Jerusalem Hadassah Medical School
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1801972773 | |
| NPPES Provider LastName | TALPAZ | |
| NPPES Provider FirstName | MOSHE | |
| NPPES Provider ZIPCode | 481095914 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 458.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1801972773 |
| Last Name Of The Provider | TALPAZ |
| First Name Of The Provider | MOSHE |
| View All |
Similar Doctors
|
|
Dr. Jeffrey B. Smerage, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan G. Urba, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Kathleen A. Cooney, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Megan E. Caram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dean E. Brenner, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Sheetal M. Kircher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David W. Brown, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Assuntina G. Sacco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sofia D. Merajver, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Muneesh Tewari, MD
This Doctor is OpenDoctor Recommended.
|